Akums Launches DCGI-Approved Triple-Action Combination Therapy for Diabetic Peripheral Neuropathic Pain

Akums Drugs and Pharmaceuticals has cleared a meaningful regulatory threshold in India's combination therapy space, securing DCGI approval for a fixed-dose combination targeting diabetic peripheral neuropathic pain, a product category where domestic regulatory pathways have historically been complex to navigate.

The formulation combines three active mechanisms in a single dosage unit, positioning it within the growing class of fixed-dose combinations (FDCs) that Indian regulators have scrutinised closely over the past decade. For regulatory affairs leads tracking Schedule Y compliance and new drug application requirements under India's drug approval framework, the clearance signals that the DCGI is continuing to evaluate multi-component combinations on a case-by-case clinical rationale basis rather than applying blanket restrictions.

The commercial context is material. India carries one of the world's largest diabetes burdens, and peripheral neuropathy, compounded by nutritional deficiencies prevalent in the population, represents a high-volume therapeutic need. For CDMOs and formulation developers assessing pipeline prioritisation, the approval demonstrates a viable domestic regulatory route for novel FDCs when the clinical rationale is adequately substantiated in the dossier.

Akums, which operates as both a CDMO and a branded generics business, brings the product to market under its own label, a structural point relevant to QA directors evaluating how vertically integrated manufacturers manage the transition from contract development to proprietary launch under a single GMP-compliant manufacturing umbrella. Post-approval process validation and stability data commitments will govern how quickly the product reaches commercial scale.

The approval also arrives as Indian regulators continue refining their FDC review criteria, making this launch a reference data point for companies preparing combination therapy dossiers for DCGI submission in adjacent therapeutic areas.

How Akums manages post-market pharmacovigilance obligations and any required Phase IV commitments attached to the DCGI clearance will determine the longer-term regulatory standing of the combination.

Source: Media4Growth via Indian Pharma Post, 30 June 2026.